Molecular Cancer Diagnostics Group's Hong Kong IPO prospectus expires, obtains regulatory approval for IVD products in the molecular cancer screening industry
1min read Mirxes Holding Company Limited-B (shortened as "Mirxes Group") filed its Hong Kong Stock Exchange IPO prospectus on April 30, 2024, which expired on October 30, with CICC and China Merchants International as joint sponsors.The prospectus shows that Mirxes Group is a miRNA technology company originated in Singapore, focusing on the global popularization of disease screening and diagnosis solutions. As of the last practicable date (April 22, 2024), the Company has one core product (i.e., GASTROClear TM), two other commercialized products (i.e., LungClearTM and FortitudeTM), and six candidate products in preclinical stage.According to Frost & Sullivan, Mirxes Group is a pioneer and leader in the development and commercialization of accurate, non-invasive, affordable, and blood-based miRNA test kits for early detection of cancer and other diseases. According to Frost & Sullivan, the Company is one of the few companies globally that has received regulatory approval for IVD products in the molecular cancer screening industry, and is the first and only company globally to receive regulatory approval for IVD products for molecular gastric cancer screening.
